Our study applied an innovative digital methodology (i.e., SIMOA), which enabled us to detect even subtle regulations in CSF, suggesting NfL as a potential diagnostic marker for a reliable discrimination either between other synucleinopathies (i.e., DLB and MSA) and PD or between other synucleinopathies and controls. The gene discussed is NEFL; the disease is synucleinopathy.